[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100241379":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":26,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Tang-Du Hospital","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"healthy control group",null,"fasting plasma glucose(FPG)\\\u003C6.11mmol\u002FL，and 2-h plasma glucose(2hPG)\\\u003C7.77mmol\u002FL；",{"label":13,"type":10,"description":14,"interventionNames":10},"prodromal diabetes group","IFG：fasting plasma glucose(FPG) ≥5.6mmol\u002FL (100mg\u002Fdl)，and\\\u003C7.0mmol\u002FL (126mg\u002Fdl)，oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) \\\u003C7.8 mmol\u002FL ；IGT：oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) ≥7.8mmol\u002FL (140mg\u002Fdl)，and\\\u003C11.1mmol\u002FL (200mg\u002Fdl)，fasting plasma glucose(FPG)\\\u003C 5.6mmol\u002FL",{"label":16,"type":10,"description":17,"interventionNames":10},"diabetes group","fasting plasma glucose(FPG)\\>7.0mmol\u002FL, or 2-h plasma glucose(2hPG)\\>11.1mmol\u002FL",[19],{"name":20,"affiliation":5,"role":21},"Guangbin Cui, professor","STUDY_CHAIR",[23],{"name":20,"role":24,"phone":10,"phoneExt":10,"email":25},"CONTACT","cgbtd@126.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Tangdu Hospital","RECRUITING","Xi'an","Shaanxi","710032","China","CN",{"type":36,"coordinates":37},"Point",[38,39],108.92861,34.25833,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":10,"email":45},"Ying Yu, master","029-18191260958","yqlmn@126.com",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100241379","the-early-warning-system-for-the-diabetic-encephalopathy-100241379",false,"NCT02420470","The Early Warning System for the Diabetic Encephalopathy","The Early Warning System for the Central Nervous System Micro-structure Alterations During Early Diabetes Based on the Multi-mode MRIs","Inclusion Criteria:\n\n* without dementia\n* Inform Consent Form\n* Education time more than 6 years\n* blood glucose matches the group standard\n\nExclusion Criteria:\n\n* Pregnant woman\n* suffer from serious brain disease\n* Magnetic resonance contraindications\n* lack of compliance\n* image quality is too poor to deal with",true,"ALL","40 Years","65 Years",{"count":60,"type":61},300,"ESTIMATED","OBSERVATIONAL","Diabetes( mainly type II diabetes )lead to the central nervous system (CNS) function impairment, especially the mild cognitive impairment that increased the risk of progression to dementia.The primary objectives are defined according to a hierarchical design: i) to tailor and apply multi-parametric, functional MRI techniques to identify cerebral abnormalities (cerebral biomarkers) in type 2 diabetes mellitus and prodromal diabetes mellitus ; ii) to assess whether these cerebral biomarkers are associated with cognitive decrements;iii) to follow up with the putative prediabetic condition patients to verify whether they can transform into diabetes.",[65,66,67],"Diabetes Mellitus Type 2","Mild Cognitive Impairment","Metabolic Syndrome X",[69,70,71],"diabetes","neural and vessel alteration","prodromal stage","2022-07-12",{"date":74,"type":75},"2022-07-13","ACTUAL",{"date":77,"type":10},"2015-04",{"date":79,"type":61},"2026-12",{"name":5,"class":6},1]